# US 2014/0155575 A1 · Process of Preparing Guanylate Cyclase C Agonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0155575 A1
- Document ID: US20140155575A1
- Status: Published application
- Kind: A1
- Application number: 14/001,638
- Filed: 2012-03-01
- Published: 2014-06-05
- Earliest claimed: 2011-03-01
- Assignees: Synergy Pharmaceuticals, Inc.
- Inventors: Juncai Bai; Ruoping Zhang; Jun Jian; Junfeng Zhou; Qiao Zhao; Guoquing Zhang; Kunwar Shailubhai; Stephen Comiskey; Rong Feng
- Web page: https://patentgrep.com/patent/US20140155575A1

## CPC

- C07K 7/64: Cyclic peptides containing only normal peptide links
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/195: from bacteria
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides processes of preparing a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-249 described herein.

## Claims

### Claim 1

A process of preparing a peptide comprising a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-249, wherein the GCC agonist sequence is n amino acid units in length, with the N-terminal unit at position 1 and the C-terminal unit at position n, the process comprising:
providing a first fragment having a first sequence of amino acid units from position j through position k of the GCC agonist sequence, wherein j is an integer between 1 and n−1, k is an integer between 2 and n and is greater than j, and the first fragment is protected except for an amino group of the amino acid unit at position j, or alternatively, a carboxyl group of the amino acid unit at position k,
providing a second fragment having a second sequence of amino acid units from position h through position j−1 of the GCC agonist sequence or having a third sequence of amino acid units from position k+1 through position m of the GCC agonist sequence, wherein h is an integer between 1 and n−2 and is smaller than j, m is an integer between k+2 and n, and the second fragment is protected except for a carboxyl group of the amino acid unit at position j−1 or an amino group of the amino acid unit at position k+1, and
coupling the first and the second fragments via a solution-phase synthesis to yield a protected peptide having a sequence of amino acid units from position h through position k of the GCC agonist sequence or a protected peptide having a sequence of amino acid units from position j through position m of the GCC agonist sequence.

### Claim 2 (depends on 1)

The process of claim 1, wherein the GCC agonist sequence is selected from the group consisting of SEQ ID NOs: 1, 8, 9, 55, 56, 58, and 59.

### Claim 3 (depends on 1)

The process of claim 1, wherein the GCC agonist sequence is selected from the group consisting of SEQ ID NOs: 1 and 9.

### Claim 4 (depends on 3)

The process of claim 3, wherein at least one of the first and second fragments is provided via a solid-phase peptide synthesis.

### Claim at position 5

5-7. (canceled)

### Claim 8 (depends on 3)

The process of claim 3, wherein h is 7, j is 15, and k is 16.

### Claim 9 (depends on 8)

The process of claim 8, further comprising deprotecting an amino group of the amino acid unit at position 7 of the protected peptide having the sequence of amino acid units from position 7 through position 16 of the GCC agonist sequence to yield a position-7 reactive peptide.

### Claim 10 (depends on 9)

The process of claim 9, further comprising providing a third fragment having a sequence of amino acid units from position 1 through position 6 of the GCC agonist sequence, wherein the third fragment is protected except for a carboxyl group of the amino acid at position 6.

### Claim at position 9

11-12. (canceled)

### Claim 13 (depends on 10)

The process of claim 10, further comprising coupling the third fragment and the position-7 reactive peptide via a solution-phase synthesis to yield a protected linear peptide having a sequence of amino acid units from position 1 through position 16 of the GCC agonist sequence.

### Claim 14 (depends on 13)

The process of claim 13, further comprising deprotecting the protected linear peptide to yield a deprotected linear peptide and oxidizing the deprotected linear peptide to yield the peptide comprising the GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1 and 9.

### Claim at position 12

15-17. (canceled)

### Claim 18 (depends on 1)

The process of claim 1, wherein each of the first and second fragments is not more than 10 amino acid units in length.

### Claim 19 (depends on 18)

The process of claim 18, wherein the second fragment has the second sequence of amino acid units from position h through position j−1 of the GCC agonist sequence and either one or both of the amino acid unit of the second fragment at position j−1 and the amino acid unit of the first fragment at position k is selected from the group consisting of glycine, proline, leucine, alanine, and arginine, or the second fragment has the third sequence of amino acid units from position k+1 through position m of the GCC agonist sequence and either one or both of the amino acid unit of the second fragment at position m and the amino acid unit of the first fragment at position k is selected from the group consisting of glycine, proline, leucine, alanine, and arginine.

### Claim at position 15

20-22. (canceled)

### Claim 23 (depends on 1)

The process of claim 1, wherein k is n, the second fragment has the second sequence of amino acid units from position h through position j−1 of the GCC agonist sequence, and the amino acid unit at positions j−1 is selected from the group consisting of glycine, proline, leucine, alanine, and arginine.

### Claim 24 (depends on 23)

The process of claim 23, further comprising deprotecting an amino group of the amino acid unit at position h of the protected peptide having a sequence of amino acid units from position h through position k of the GCC agonist sequence to yield a position-h reactive peptide.

### Claim at position 18

25-28. (canceled)

### Claim 29 (depends on 24)

The process of claim 24, further comprising providing a fourth fragment having a sequence of amino acid units from position 1 through position h−1 of the GCC agonist sequence, wherein the fourth fragment is protected except for a carboxyl group of the amino acid unit at position h−1, and
coupling the fourth fragment and the position-h reactive peptide via a solution-phase synthesis to yield a protected linear peptide having a sequence of amino acid units from position 1 through position n of the GCC agonist sequence.

### Claim 30 (depends on 29)

The process of claim 29, further comprising deprotecting the protected linear peptide to yield a deprotected linear peptide having a sequence of amino acid units from position 1 through position n of the GCC agonist sequence and oxidizing the deprotected linear peptide to yield the peptide comprising the GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-249.

### Claim at position 21

31-36. (canceled)

### Claim 37

A process of purifying the peptide comprising the GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-249, the process comprising adsorbing the peptide onto a polymeric adsorbent column, desalting the peptide, eluting the desalted peptide off the polymeric adsorbent column with an alcohol aqueous solution to form a peptide solution, removing water from the peptide solution, and adding an ether to the dewatered peptide to precipitate the peptide.

### Claim at position 23

38-41. (canceled)

### Claim 42

A purified peptide comprising the GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-249, wherein the peptide has a bulk density of no less than 0.1 g/mL, no less than 0.2 g/mL, no less than 0.3 g/mL, no less than 0.4 g/mL, or no less than 0.5 g/mL.

### Claim at position 25

43-47. (canceled)

### Claim 48 (depends on 42)

The purified peptide of claim 42, wherein peptide is substantially free of impurities selected from acetonitrile, acetamide, alcohols, ammonium, and TFA.

### Claim 49 (depends on 42)

The purified peptide of claim 42, wherein the peptide is substantially free of topoisomers.

### Claim 50 (depends on 42)

The purified peptide of claim 42, wherein the peptide comprises the GCC agonist sequence of SEQ ID NO: 1 or 9.

### Claim 51

(canceled)
